Antiepileptika bei Frauen im gebärfähigen Alter und in der Schwangerschaft : Vergleich der Fachinformationen in Deutschland und der Schweiz mit dem aktuellen Wissensstand [Antiepileptics in women of childbearing age and during pregnancy : Comparison of specialized information with the current state of knowledge in Germany and Switzerland].

Détails

Ressource 1Télécharger: 90.pdf (1083.11 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_72BDC14B7721
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Antiepileptika bei Frauen im gebärfähigen Alter und in der Schwangerschaft : Vergleich der Fachinformationen in Deutschland und der Schweiz mit dem aktuellen Wissensstand [Antiepileptics in women of childbearing age and during pregnancy : Comparison of specialized information with the current state of knowledge in Germany and Switzerland].
Périodique
Der Nervenarzt
Auteur⸱e⸱s
Winterfeld U., Gotta V., Rothuizen L.E., Panchaud A., Rossetti A.O., Buclin T.
ISSN
1433-0407 (Electronic)
ISSN-L
0028-2804
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
85
Numéro
6
Pages
738-746
Langue
allemand
Notes
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish
Résumé
BACKGROUND: Healthcare professionals regularly read the summary of product characteristics (SmPC) as one of the various sources of information on the risks of drug use in women of childbearing age and during pregnancy. The aim of this article is to present an overview of the teratogenic potential of various antiepileptic drugs and to compare these data with the information provided by the SmPCs.
METHODS: A literature search on the teratogenic risks of 19 antiepileptic agents was conducted and the results were compared with the information on the use in women of childbearing age and during pregnancy provided by the SmPCs of 38 commercial products available in Switzerland and Germany.
RESULTS: The teratogenic risk is discussed in all available SmPCs. Quantification of the risk for birth defects and the numbers of documented pregnancies are mostly missing. Reproductive safety information in SmPCs showed poor concordance with risk levels reported in the literature. Recommendations concerning the need to monitor plasma levels and possibly perform dose adjustments during pregnancy to prevent treatment failure were missing in five Swiss and two German SmPCs.
DISCUSSION: The information regarding use in women of childbearing age and during pregnancy provided by the SmPCs is heterogeneous and poorly reflects the current state of knowledge. Regular updates of SmPCs are warranted in order for these documents to be of reliable use for health care professionals.
Pubmed
Web of science
Création de la notice
26/06/2014 19:00
Dernière modification de la notice
09/09/2021 7:11
Données d'usage